
Sign up to save your podcasts
Or


Dr. Greg Riely from Memorial Sloan-Kettering reviews strategies for managing acquired resistance to EGFR inhibitors and other targeted therapies in advanced non-small cell lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.
Dr. Lecia Sequist describes the state of the art and her view of current best practices on molecular testing for advanced non-small cell lung cancer.
Dr. Geoffrey Oxnard describes the new finding of individuals with an inherited T790M mutation in the EGFR gene, the unclear significance of it, and a study being conducted to learn more about it.
Dr. William Pao describes the MyCancerGenome.org website and how data on a wide range of mutations is incorporated to build this database to help physicians and cancer patients identify the most promising targeted therapy options for them.
From the publisher's feed